Interstitial lung disease: A review | ||
| Journal of Advanced Biomedical and Pharmaceutical Sciences | ||
| Article 1, Volume 8, Issue 1, January 2025, Pages 1-6 PDF (427.23 K) | ||
| Document Type: Review Articles | ||
| DOI: 10.21608/jabps.2024.320282.1222 | ||
| Authors | ||
| Hanan Omar Eldawy* 1; Mahmoud Elrehany2; Amany Bekhit3; Khaled Thabet4 | ||
| 1Department of biochemistry, Faculty of Pharmacy, Minia University, Minia, Egypt. | ||
| 2Department of Biochemistry, Faculty of Pharmacy, Deraya University, Minia, Egypt. | ||
| 3Department of Biochemistry, Faculty of Pharmacy, Minia University, Minia, Egypt | ||
| 41Department of biochemistry, Faculty of Pharmacy, Minia University, Minia, Egypt. | ||
| Abstract | ||
| Interstitial lung disease (ILD) is a term used to describe various lung conditions characterized by inflammation and, less commonly, fibrosis. Idiopathic pulmonary fibrosis is one of the most lethal ILDs, exhibiting a broad spectrum of clinical manifestations. Common symptoms of ILD are dyspnea (shortness of breath), coughing, abnormalities in gas exchange, reduced lung volumes, hypoxemia, and, in severe cases, respiratory failure. A preexisting medical condition or environmental variables may set off an ILD. Many ILDs have treatment options or even a cure, depending on the subtypes. Lung transplantation, however, is the sole curative choice in some instances. Evidence shows that common and unusual genetic variants can influence various ILDs. | ||
| Keywords | ||
| Interstitial lung diseases (ILDs); idiopathic pulmonary fibrosis (IPF); Connective tissue disorders (CTDs); Pulmonary fibrosis (PF); and Rheumatoid arthritis (RA) | ||
|
Statistics Article View: 187 PDF Download: 412 |
||
